Uterine cavity lesions
Conditions
Interventions
Premenopausal group:The initial dose of nalbuphine is 0.15 mg/kg. Subsequent doses for each patient are determined based on the response of the preceding patient. If satisfactory analgesia is achieved
Postmenopausal Group:The initial dose of nalbuphine is 0.15 mg/kg. Subsequent doses for each patient are determined based on the response of the preceding patient. If satisfactory analgesia is achieve
Sponsors
Hangzhou Fuyang Women And Children Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients aged 18~70 years old who underwent elective day hysteroscopic surgery; (2) ASA Grading I ~II; (3)BMI 18.5~28.0 kg/m^2.
Exclusion criteria
Exclusion criteria: (1) Allergy to nalbuphine or propofol; (2) Suspected or confirmed history of long-term use of anesthetic drugs and sedative drugs; (3) History of sleep apnea syndrome; (4) Difficult airway; (5) Those who have mental or neurological disorders that affect cognitive function and do not cooperate well with physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 90% effective dose of nalbuphine for analgesia in day-case hysteroscopy procedures.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure;Heart rate;Pulse oxygen saturation;Duration of surgery;Time from drug withdrawal to awakening;Time from eye opening to recovery of orientation;Total dose of propofol administered; | — |
Countries
China
Contacts
Public ContactPing Xu
Hangzhou Fuyang Women And Children Hospital
Outcome results
None listed